Korea Accelerates Nipah Virus Drug & Vaccine Development

South Korea is accelerating development of a vaccine for the Nipah virus, with clinical trials slated to begin in 2029, according to reports from The Chosun Ilbo. The initiative, a collaboration between EuBiologics and the Korea Disease Control and Prevention Agency (KDCA), aims to bolster the nation’s pandemic preparedness against the highly lethal virus.

The partnership between EuBiologics and the KDCA was formalized to advance a Nipah virus vaccine candidate, as reported by The Korea Economic Daily Global Edition and koreabiomed.com. The KDCA’s involvement underscores the government’s commitment to proactively addressing potential pandemic threats.

Nipah virus, identified as a significant public health concern, has a high fatality rate – approximately 75% according to The Chosun Ilbo – and can cause severe respiratory illness and encephalitis. The virus is typically transmitted to humans from fruit bats, or through contaminated food, and can also spread between people.

This development is part of a broader South Korean strategy to strengthen its defenses against infectious diseases, as highlighted by Dong-A Science. The initiative reflects a growing global focus on pandemic preparedness following recent health crises.

EuBiologics is responsible for the vaccine candidate’s development, while the KDCA provides support and oversight. The planned clinical trials in 2029 will be crucial in assessing the vaccine’s safety and efficacy.